Charles Schwab Investment Management Inc. Purchases 10,262 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT)

Charles Schwab Investment Management Inc. raised its position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) by 1.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 916,743 shares of the company’s stock after purchasing an additional 10,262 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.62% of Adaptive Biotechnologies worth $4,694,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in ADPT. JTC Employer Solutions Trustee Ltd bought a new stake in Adaptive Biotechnologies in the third quarter worth approximately $26,000. Ashton Thomas Securities LLC bought a new stake in shares of Adaptive Biotechnologies during the third quarter valued at approximately $34,000. Rothschild Investment LLC bought a new stake in shares of Adaptive Biotechnologies during the second quarter valued at approximately $36,000. MQS Management LLC bought a new stake in shares of Adaptive Biotechnologies during the second quarter valued at approximately $36,000. Finally, Nisa Investment Advisors LLC increased its holdings in shares of Adaptive Biotechnologies by 769.6% during the second quarter. Nisa Investment Advisors LLC now owns 13,392 shares of the company’s stock valued at $48,000 after acquiring an additional 11,852 shares in the last quarter. 99.17% of the stock is currently owned by institutional investors.

Adaptive Biotechnologies Stock Performance

NASDAQ:ADPT opened at $6.30 on Friday. The firm has a market cap of $929.75 million, a price-to-earnings ratio of -4.70 and a beta of 1.49. The business’s fifty day moving average is $5.37 and its 200 day moving average is $4.57. Adaptive Biotechnologies Co. has a 52-week low of $2.28 and a 52-week high of $7.07.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on ADPT shares. BTIG Research lifted their target price on Adaptive Biotechnologies from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Wednesday, October 2nd. Piper Sandler lifted their target price on Adaptive Biotechnologies from $6.00 to $7.00 and gave the company an “overweight” rating in a research report on Monday, November 11th.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.